logo
Plus   Neg
Share
Email

Golden Biotechnology: FDA Approves Phase II Trial Of Antroquinonol On COVID-19 Patients

Golden Biotechnology Corp., a Taiwanese biopharmaceutical company, said the FDA approved its investigational new drug application for a Phase II clinical trial of Antroquinonol (Hocena) on COVID-19 patients in USA. The phase II trial will be a randomized, double-blinded, placebo-controlled study of Antroquinonol as a potential treatment option for mild-to-moderate pneumonia in COVID-19 patients, as measured by the proportion of patients alive and free of respiratory failure on day 14.

GoldenBiotech has also applied for the US BARDA CoronaWatch meeting.

For comments and feedback contact: editorial@rttnews.com

Follow RTT